SCHEMBL855051

SCHEMBL855051

CCC1(C(=O)O)CCNCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.38
KDM4E B2RXH2 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP2C19 P33261 1/20 0.35
FFAR3 O14843 1/20 0.33
SLC6A2 P23975 6/20 0.32
SLC6A4 P31645 6/20 0.32
SLC6A3 Q01959 6/20 0.32
CYP2D6 P10635 5/20 0.32
SMYD3 Q9H7B4 2/20 0.30
GABRP O00591 1/20 0.30
GABRD O14764 1/20 0.30
GABRA1 P14867 1/20 0.30
TSHR P16473 1/20 0.30
GABRB1 P18505 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30
GABRA5 P31644 1/20 0.30
GABRA3 P34903 1/20 0.30
GABRA2 P47869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL29516278 0.92 OPRM1 (0.34) OPRM1KDM4EKMT2ACYP2C19
SCHEMBL31693661 0.88 CYP1A2 (0.37) OPRM1KDM4EKMT2ACYP2C19CYP2D6
SCHEMBL29951019 0.87 SLC6A2 (0.39) OPRM1CYP2C19SLC6A2SLC6A4SLC6A3
Chlorobenzene SCHEMBL28751598 0.83 OPRM1 (0.44) OPRM1SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL30716833 0.83 CYP2C19 (0.42) CYP2C19FFAR3SLC6A3
SCHEMBL245571 0.83
SCHEMBL1292699 0.83 CYP2D6 (0.41) OPRM1KDM4EKMT2ACYP2C19SLC6A2
Hydrochloric Acid SCHEMBL11173735 0.80
SCHEMBL29090668 0.80 KDM4E (0.48) OPRM1KDM4EKMT2ASMYD3
SCHEMBL4294182 0.79 CYP2C19 (0.37) OPRM1KDM4EKMT2ACYP2C19SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN claimed
EP-3215489-B1 METHOD FOR THE PREPARATION OF 1-(2-HALOGEN-ETHYL)-4 PIPERIDINE-CARBOXYLIC ACID ETHYL ESTERS OLON SPA (IT) 2019-07-24 EP claimed
US-10023535-B2 Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters OLON S.P.A. (IT) 2018-07-17 US claimed
US-20170313657-A1 METHOD FOR THE PREPARATION OF 1-(2-HALOGEN-ETHYL)-4 PIPERIDINE-CARBOXYLIC ACID ETHYL ESTERS OLON S.P.A. (IT) 2017-11-02 US claimed
EP-3215489-A1 METHOD FOR THE PREPARATION OF 1-(2-HALOGEN-ETHYL)-4 PIPERIDINE-CARBOXYLIC ACID ETHYL ESTERS OLON S.p.A. (IT) 2017-09-13 EP claimed
WO-2016071792-A1 METHOD FOR THE PREPARATION OF 1-(2-HALOGEN-ETHYL)-4 PIPERIDINE-CARBOXYLIC ACID ETHYL ESTERS LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) 2016-05-12 WO claimed
EP-0387057-B1 Surface-treating agents for copper and copper alloy TOKAI ELECTRO CHEMICAL CO (JP) 1993-10-20 EP claimed
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 CN disclosed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 CN disclosed
US-20240299627-A1 Inverse thermogelling polyoxazoline copolymers JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) 2024-09-12 US disclosed
EP-0300462-B1 HETEROCYCLIC PEROXYCARBOXYLIC ACIDS AUSIMONT S.p.A. (IT) 1993-09-29 EP disclosed
EP-0292735-B1 PROCESS FOR PREPARING ALPHA-(ALKYLPHENYL)-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINE BUTANOL ERREGIERRE INDUSTRIA CHIMICA Spa (IT) 1992-08-19 EP disclosed
US-5112978-A Preparation of terfenadine ERREGIERRE INDUSTRIA CHIMICA S.P.A. (IT) 1992-05-12 US disclosed
US-5071584-A Storage stable, heat resistant AUSIMONT S.P.A. (IT) 1991-12-10 US disclosed
US-4950674-A Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment A. H. ROBINS COMPANY, INCORPORATED (US) 1990-08-21 US disclosed
EP-0300462-A2 Heterocyclic peroxycarboxylic acids AUSIMONT S.p.A. (IT) 1989-01-25 EP disclosed
EP-0068669-A1 Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application BEECHAM GROUP PLC (GB) 1983-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023535-B2 Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters UMPS, UCK2, EFTUD2 OPRM1 932/4885KDM4E 152/4885KMT2A 2887/4885
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA OPRM1 4717/4885KDM4E 1315/4885KMT2A 2132/4885
US-20170313657-A1 METHOD FOR THE PREPARATION OF 1-(2-HALOGEN-ETHYL)-4 PIPERIDINE-CARBOXYLIC ACID ETHYL ESTERS UMPS, UCK2, EFTUD2 OPRM1 932/4885KDM4E 152/4885KMT2A 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.